VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.50 price objective on shares of VolitionRx in a research report on Wednesday, March 27th.

VolitionRx Price Performance

VolitionRx stock opened at $0.89 on Friday. The company has a market capitalization of $73.12 million, a PE ratio of -1.75 and a beta of 1.26. VolitionRx has a one year low of $0.55 and a one year high of $2.09. The business has a 50 day simple moving average of $0.83 and a 200 day simple moving average of $0.85.

VolitionRx (NYSE:VNRX) last posted its earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.50 million. Equities analysts anticipate that VolitionRx will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of VolitionRx Limited (NYSE:VNRX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.